Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 11/20 | 0.67 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | BLVRB | P30043 | 1/20 | 0.49 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17134262 | 0.92 | XDH (0.79) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL17134461 | 0.89 | XDH (0.83) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL17134414 | 0.80 | XDH (1.00) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL20195698 | 0.80 | XDH (0.66) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL15512218 | 0.80 | XDH (1.00) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL29010159 | 0.74 | XDH (0.56) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL3583167 | 0.74 | XDH (0.53) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL19523355 | 0.74 | XDH (0.68) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL25327616 | 0.74 | XDH (0.60) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL31601 | 0.74 | XDH (0.80) | XDHABCC4ABCB11PGRCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2927219-B1 | 2-ARYL SELENAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2018-05-30 | — | — | EP | disclosed |
| US-9802907-B2 | 2-aryl selenazole compound and pharmaceutical composition thereof | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2017-10-31 | — | — | US | disclosed |
| US-20150291543-A1 | 2-ARYL SELENAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD.(CN) (CN) | 2015-10-15 | — | — | US | disclosed |
| EP-2927219-A1 | 2-ARYL SELENAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | Atom Bioscience and Pharmaceutical Co. Ltd. (CN) | 2015-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291543-A1 | 2-ARYL SELENAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | SCLY, XDH, SELENOI | XDH 2/4885ABCC4 1210/4885ABCB11 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.